Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jerry M Adams

Showing results (51-60 of 59) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 59 results.
The Journal of Cell Biology|September 4, 2003
Proapoptotic BH3-only proteins trigger membrane integration of prosurvival Bcl-w and neutralize its activityJulie Wilson-Annan, Lorraine A O'Reilly, Simon A Crawford, et al.
Cell|February 5, 2013
Bax crystal structures reveal how BH3 domains activate Bax and nucleate its oligomerization to induce apoptosisPeter E Czabotar, Dana Westphal, Grant Dewson, et al.
Cancer Cell|November 14, 2006
The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralizedMark F van Delft, Andrew H Wei, Kylie D Mason, et al.
Science (New York, N.Y.)|February 10, 2007
Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or BakSimon N Willis, Jamie I Fletcher, Thomas Kaufmann, et al.
Nature|October 11, 2002
Apoptosis initiated by Bcl-2-regulated caspase activation independently of the cytochrome c/Apaf-1/caspase-9 apoptosomeVanessa S Marsden, Liam O'Connor, Lorraine A O'Reilly, et al.
Blood|September 1, 2021
Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLLPiers Blombery, Thomas E Lew, Michael A Dengler, et al.
Nature Chemical Biology|April 23, 2013
Structure-guided design of a selective BCL-X(L) inhibitorGuillaume Lessene, Peter E Czabotar, Brad E Sleebs, et al.
Blood|October 11, 2022
Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemiaDonia M Moujalled, Fiona C Brown, Chong Chyn Chua, et al.
Journal of Medicinal Chemistry|June 18, 2013
Discovery of potent and selective benzothiazole hydrazone inhibitors of Bcl-XLBrad E Sleebs, Wilhemus J A Kersten, Sanji Kulasegaram, et al.
Pageof 6

Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
The Journal of Cell Biology|September 4, 2003
Proapoptotic BH3-only proteins trigger membrane integration of prosurvival Bcl-w and neutralize its activityJulie Wilson-Annan, Lorraine A O'Reilly, Simon A Crawford, et al.
Cell|February 5, 2013
Bax crystal structures reveal how BH3 domains activate Bax and nucleate its oligomerization to induce apoptosisPeter E Czabotar, Dana Westphal, Grant Dewson, et al.
Cancer Cell|November 14, 2006
The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralizedMark F van Delft, Andrew H Wei, Kylie D Mason, et al.
Science (New York, N.Y.)|February 10, 2007
Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or BakSimon N Willis, Jamie I Fletcher, Thomas Kaufmann, et al.
Nature|October 11, 2002
Apoptosis initiated by Bcl-2-regulated caspase activation independently of the cytochrome c/Apaf-1/caspase-9 apoptosomeVanessa S Marsden, Liam O'Connor, Lorraine A O'Reilly, et al.
Blood|September 1, 2021
Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLLPiers Blombery, Thomas E Lew, Michael A Dengler, et al.
Nature Chemical Biology|April 23, 2013
Structure-guided design of a selective BCL-X(L) inhibitorGuillaume Lessene, Peter E Czabotar, Brad E Sleebs, et al.
Blood|October 11, 2022
Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemiaDonia M Moujalled, Fiona C Brown, Chong Chyn Chua, et al.
Journal of Medicinal Chemistry|June 18, 2013
Discovery of potent and selective benzothiazole hydrazone inhibitors of Bcl-XLBrad E Sleebs, Wilhemus J A Kersten, Sanji Kulasegaram, et al.
Pageof 6